Deutsche Bank’s Inhibikase Therapeutics IKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$228K Sell
110,779
-15,898
-13% -$36.2K ﹤0.01% 3023
2026
Q2
$257K Buy
126,677
+4,235
+3% +$7.58K ﹤0.01% 3124
2026
Q1
$206K Buy
122,442
+67,533
+123% +$120K ﹤0.01% 2995
2025
Q4
$113K Sell
54,909
-25,587
-32% -$40.7K ﹤0.01% 3258
2025
Q3
$130K Buy
+80,496
New +$139K ﹤0.01% 3253

Other funds holding IKT

Deutsche Bank's IKT Position: Q3 2026 in Review

Deutsche Bank reduced its Inhibikase Therapeutics (IKT) stake by 13% in Q3 2026, selling an estimated $36.2K and leaving 110,779 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #3023.

Deutsche Bank first reported a position in IKT in Q3 2025 and has held it in 5 quarters since. The position peaked at $257K in Q2 2026. 110 funds tracked by Wall St. Rank hold IKT as of Q3 2026.

  • Deutsche Bank held 110,779 shares of Inhibikase Therapeutics worth $228K as of Q3 2026.
  • Deutsche Bank sold 15,898 Inhibikase Therapeutics shares in Q3 2026, an estimated $36.2K.
  • Inhibikase Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #3023 holding.
  • Deutsche Bank first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Deutsche Bank's Inhibikase Therapeutics position peaked at $257K in Q2 2026.
  • 110 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.